Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis
NCT: NCT05661266 · COMPLETED
Brief Summary
The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in multiple sclerosis (MS) patients to further build up a database of MS patients and train a machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status.
Frequently Asked Questions
What is Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis?
Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis is a clinical trial registered under NCT05661266. Current status: COMPLETED.
What is the status of NCT05661266?
The current status of NCT05661266 (Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis) is: COMPLETED.
When did Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis start?
Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis started on 2023-08-16.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.